Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 9127045
Method of inhibiting bacterial growth and biofilm formation with natural quorum sensing peptides
granted -
US 9119837
Use of sEH inhibitors as analgesics
granted -
US 9119884
LLP2A-bisphosphonate conjugates for osteoporosis treatment
granted -
US 9121016
Coatings containing polymer modified enzyme for stable self-cleaning of organic stains
granted -
US 9121852
Carcinoma diagnosis and treatment, based on ODC1 genotype
granted -
US 9119832
Methods of treating mild brain injury
granted -
US 9119823
Nitrite formulations and their use as nitric oxide prodrugs
granted -
US 9119863
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
granted -
US 9119773
Toroidal pharmaceutical formulations
granted -
US 9120872
Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
granted -
US 9120744
Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
granted -
US 9114173
Vault and vault like carrier molecules
granted -
US 9115120
Heterocyclic modulators of HIF activity for treatment of disease
granted -
US 9115193
VMP-like sequences of pathogenic Borrelia species and strains
granted -
US 9107897
Methods for isolating mammalian retinal progenitor cells
granted -
US 9107940
Compositions and methods for treating and preventing skeletal muscle deficiencies
granted -
US 9110064
Methods for diagnosis and treatment of endometrial cancer
granted -
US 9107883
Compounds and methods for treating aberrant adrenocartical cell disorders
granted -
US 9102626
Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
granted -
US 9101637
Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity
granted -
US 9103826
Methods and biomarkers for the detection of dengue hemorrhagic fever
granted -
US 9102940
RNAi modulation of SCAP and therapeutic uses thereof
granted -
US 9096499
Compounds for treatment of cell proliferative diseases
granted -
US 9096501
Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
granted -
US 9095608
Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
granted -
US 9095579
Protection and treatment against influenza infection
granted -
US 9095562
Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
granted -
US 9095572
Pro-neurogenic compounds
granted -
US 9095550
Methods for treating diabetic wounds
granted -
US 9095571
Pro-neurogenic compounds
granted -
US 9096830
Multi-layered hydrogel constructs and associated methods
granted -
US 9096679
Peptide compounds and methods of production and use thereof
granted -
US 9096647
Simplified one-pot synthesis of [18F]SFB for radiolabeling
granted -
US 9095558
Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
granted -
US 9097707
Photoreactive regulator of protein function and methods of use thereof
granted -
US 9096625
BCL-2/BCL-XL inhibitors and therapeutic methods using the same
granted -
US 9089545
Small molecule RNase inhibitors and methods of use
granted -
US 9089498
Multifunctional nanoparticle designs and applications
granted -
US 9091701
Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
granted -
US 9091696
Modulation of NR2F6 and methods and uses thereof
granted -
US 9090589
Specific nNOS inhibitors for the therapy and prevention of human melanoma
granted -
US 9089698
Method and apparatus for optogenetic treatment of blindness including retinitis pigmentosa
granted -
US 9089556
Method for treating cancer using an antibody that inhibits notch4 signaling
granted -
US 9089555
Complement antagonists and uses thereof
granted -
US 9089531
GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
granted -
US 9089677
Transcutaneous multimodal delivery system (TMDS)
granted -
US 9085644
Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
granted -
US 9085757
Production of insulin producing cells
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory